Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Cefadroxil
Drug ID BADD_D00379
Description Long-acting, broad-spectrum, water-soluble, cephalexin derivative.
Indications and Usage For the treatment of the following infections (skin, UTI, ENT) caused by; S. pneumoniae, H. influenzae, staphylococci, S. pyogenes (group A beta-hemolytic streptococci), E. coli, P. mirabilis, Klebsiella sp, coagulase-negative staphylococci and Streptococcus pyogenes
Marketing Status approved; vet_approved; withdrawn
ATC Code J01DB05
DrugBank ID DB01140
KEGG ID D00257; D02353
MeSH ID D002434
PubChem ID 47965
TTD Drug ID D0X9ZC
NDC Product Code 16714-390; 43063-553; 57237-096; 57237-098; 63629-7987; 63629-8253; 66267-045; 68180-180; 68788-8479; 65862-359; 16714-389; 72189-445; 80425-0198; 65862-085; 50090-6050; 63629-7988; 68180-182; 68071-5234; 16714-388; 45865-503; 63187-883; 68071-2752; 70518-2538; 50090-0580; 57237-097; 68788-7484; 68788-8261; 0093-3196; 0093-4059; 43063-595; 65862-083; 65862-084; 70518-3580; 72189-103; 50090-6356; 55289-589; 68180-181; 67296-1038; 68071-2938; 53002-2290
UNII 280111G160
Synonyms Cefadroxil | Cephadroxyl | Cefadroxil Anhydrous | 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((amino(4-hydroxyphenyl)acetyl)amino)-3-methyl-8-oxo-, (6R-(6alpha,7beta(R*)))- | Ultracef | Bidocef | Duricef | BL-S 578 | BL S 578 | BLS 578 | BL-S578 | BL S578 | BLS578 | S-578 | S 578 | S578 | 4-Hydroxycephalexin | 4 Hydroxycephalexin | Cefadroxil Monohydrate
Chemical Information
Molecular Formula C16H17N3O5S
CAS Registry Number 50370-12-2
SMILES CC1=C(N2C(C(C2=O)NC(=O)C(C3=CC=C(C=C3)O)N)SC1)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Erythema multiforme23.03.01.003; 10.01.03.0150.000836%
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal pain07.01.05.005--
Genital candidiasis11.03.03.002; 21.10.03.001--Not Available
Haemoglobin13.01.05.018--Not Available
Haemolytic anaemia01.06.03.002--Not Available
Headache17.14.01.001--
Hepatic failure09.01.03.002--
Hepatic function abnormal09.01.02.001--Not Available
Hypersensitivity10.01.03.0030.000558%
Infertility21.03.02.001--Not Available
Linear IgA disease10.04.02.006; 23.03.01.0150.000558%Not Available
Mouth ulceration07.05.06.0040.000558%Not Available
Muscle spasms15.05.03.004--
Nausea07.01.07.001--
Nephropathy toxic20.05.03.002; 12.03.01.010--Not Available
Nervousness19.06.02.003--Not Available
Neutropenia01.02.03.004--Not Available
Pain08.01.08.0040.000836%
Pancytopenia01.03.03.003--Not Available
Prothrombin level increased13.01.02.011--Not Available
Prothrombin time prolonged13.01.02.012--Not Available
Pruritus23.03.12.0010.000558%
Pruritus genital21.10.01.002; 23.03.12.008--Not Available
Pseudomembranous colitis11.02.02.002; 07.19.01.003--Not Available
Pyrexia08.05.02.0030.000558%
Rash23.03.13.001--Not Available
Rash maculo-papular23.03.13.0040.001115%
Respiratory failure14.01.04.003; 22.02.06.0020.000558%
Seizure17.12.03.001--
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages